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ABSTRACT
Despite advances in ex vivo expansion of cord blood-derived hematopoietic stem/progenitor cells
(CB-HSPC), challenges still remain regarding the ability to obtain, from a single unit, sufficient num-
bers of cells to treat an adolescent or adult patient. We and others have shown that CB-HSPC can
be expanded ex vivo in two-dimensional (2D) cultures, but the absolute percentage of the more
primitive stem cells decreases with time. During development, the fetal liver is the main site of
HSPC expansion. Therefore, here we investigated, in vitro, the outcome of interactions of primitive
HSPC with surrogate fetal liver environments. We compared bioengineered liver constructs made
from a natural three-dimensional-liver-extracellular-matrix (3D-ECM) seeded with hepatoblasts,
fetal liver-derived (LvSt), or bone marrow-derived stromal cells, to their respective 2D culture
counterparts. We showed that the inclusion of cellular components within the 3D-ECM scaffolds
was necessary for maintenance of HSPC viability in culture, and that irrespective of the microenvir-
onment used, the 3D-ECM structures led to the maintenance of a more primitive subpopulation of
HSPC, as determined by flow cytometry and colony forming assays. In addition, we showed that
the timing and extent of expansion depends upon the biological component used, with LvSt pro-
viding the optimal balance between preservation of primitive CB HSPC and cellular differentiation.
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SIGNIFICANCE STATEMENT
During development, the fetal liver is the main site of hematopoietic stem/progenitor cell
(HSPC) expansion. Herein, the authors manufactured unique constructs built upon a natural 3-D
liver extracellular matrix, into which seeded fetal liver-derived stromal cells (LvSt), or hepato-
blasts (HpB), become functionally integrated and assembled, and investigated the outcome of
HSPC interactions with these microenvironmental-mimetic niches. Since little is known about
individual fetal liver niches that support HSPC expansion, the 3-D constructs provide a model
system in which to dissect the role of its individual cellular and matrix components in support-
ing CB maintenance, expansion, and differentiation. The results showed that, irrespective of the
microenvironment used, the 3D-ECM structures led to the maintenance of a more primitive
subpopulation of HSPC. In addition, it was shown that the timing and extent of expansion
depended upon the biological component used, with HpB promoting the expansion of func-
tional immature multipotent hematopoietic progenitor cells, and LvSt providing the optimal bal-
ance between preservation of primitive CB HSPC and expansion/differentiation.
INTRODUCTION
Despite the advances made in ex vivo expansion
of cord blood-derived hematopoietic stem and
progenitor cells (CB-HSPC), challenges still remain
regarding the ability to obtain, from a single unit,
sufficient numbers of both long-and short-term
repopulating cells, capable of functional
engraftment, to enable the treatment of an ado-
lescent or adult patient [1–3].
We have previously shown that we can effec-
tively expand CB-HSPC and drive the differentia-
tion of these cells toward both the myeloid and
lymphoid lineages in a serum-free culture system,
using a feeder layer of adult human bone marrow
(BM)-derived stromal cells [4–7]. Using this
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CORD BLOOD
system, we have optimized initial progenitor content and cytokine
concentrations [7–9], and demonstrated that the expanded cells
had the ability to engraft pre-immune animals [5]. Although the
number of long-term engrafting hematopoietic stem cells (HSC)
amplified in this culture system, due to the overall increase in cell
numbers, the absolute percentage growth of these most primitive
stem cells decreased with time in culture.
Recently, we developed three-dimensional (3D), liver extracel-
lular matrix (ECM)-derived scaffolds [10, 11], that, when seeded
with human fetal liver cells, create a hepatic-like tissue in vitro, in
which hepatoblasts (HpB) and endothelial cells engraft in their
putative native locations, and display typical endothelial, hepatic,
and biliary epithelial markers [12, 13]. In these unique constructs,
human fetal liver progenitor cells self-assemble inside the ECM-
derived scaffolds to form 3D liver organoids that recapitulate sev-
eral aspects of the hepato-biliary ontogeny [14], allowing us to
investigate the effects of these surrogate fetal liver environments
on CB-HSPC.
It is well known that, during development, the fetal liver is the
main site of HSC expansion and differentiation [15]. Within the
fetal liver, HSC actively cycle, and these cells outcompete adult
HSC upon transplantation [15, 16]. Thus, hepatic tissue contains
cellular niches that lead to true expansion, or, at the least, mainte-
nance of primitive HSC [17, 18]. Although CB-HSPC possess intrin-
sic properties that confer greater proliferation capacity and
clonogenic potential [19, 20], the initial divisional behavior of CB-
HSPC is also dependent upon the environment [21]. For example,
the stromal cell line AFT024 and fetal HpB, both of murine origin,
have been shown, in two-dimensional (2D) cultures, to effectively
preserve the self-renewal capacity of human and mouse HSC,
respectively [21, 22]. In addition, endothelial cells [23, 24] and
stromal cells/pericytes associated with portal vessels have
recently been shown to play an important role in promoting CB
expansion and fetal hematopoiesis, respectively [3].
Here, we developed an “in vitro” approach to investigate the
effect of different 3D microenvironments on a primitive subpopula-
tion of human CB-derived CD341 CD382 hematopoietic progeni-
tor cells [25]. To this end, we seeded HpB or stromal cells/pericytes,
both derived from fetal liver, in a natural 3D ECM to create distinct
hepatic-like fetal niche constructs. Moreover, to determine whether
liver-derived cells were essential to the generation of the 3D micro-
environments, we also seeded adult BM-derived stromal cells/peri-
cytes in the same 3D matrix as a control. These functionally
integrated 3D milieus were then compared with their 2D culture
counterparts.We showed that, overall, 3Dmicroenvironments were
better able to support the absolute percentage growth of CD341
CD382 cells in culture, and earlier CD331myeloid progenitors.
MATERIALS AND METHODS
Three-Dimensional ECM-Derived Scaffolds (3D-ECM)
Disks
Four to five week-old ferret livers (Marshall Bioresources, North
Rose, NY) were decellularized as previously described in detail
[26], separated into lobes, embedded in plastic molds using opti-
mum cutting temperature (OCT) formulation of water-soluble gly-
cols and resins (Sakura Finetek, Torrance, CA), and flash frozen
with liquid nitrogen. Cryopreserved decellularized liver lobes were
mounted onto a Leica CM1950 cryotome (Leica Biosystems,
Buffalo Grove, IL) set at 288C to 2108C, in order to maintain the
liver lobes at warmer temperatures, thereby facilitating thick and
intact sectioning of liver lobes at 300 lm thickness. To generate
scaffold disks from liver sections, an 8-mm diameter biopsy punch,
equipped with a plunger (Medline Industries, Mundelein, IL) was
used. The disks were placed in a 48 well plate, and air-dried for up
to 4–6 hours, after which they were washed carefully with multi-
ple washes of phosphate-buffered saline (PBS), and stored in PBS
at 48C until ready for sterilization by gamma irradiation at a dose
of 15Gy (J.L. Shepherd and Associates, Inc., San Fernando, CA).
These scaffolds are comprised of highly conserved proteins and
heavily cross-linked extracellular matrix (ECM) components like
collagens, elastin, fibronectin, laminin, and proteoglycans, which
retain the characteristic 3D architecture of the native liver [10,
11]. Human fetal HpB and stromal cells can repopulate these scaf-
folds, engrafting in their putative native locations, and displaying
typical hepatic and biliary epithelial markers. These repopulated
constructs express markers characteristic of the human fetal liver,
such as albumin and a-fetoprotein, they secrete urea, and they
metabolize drugs, proving this approach can create functional, bio-
engineered liver tissue in vitro [12, 13].
Isolation and Culture of Human Fetal Liver Stromal Cells
and HpB
Human fetal livers, between 18 and 20 weeks of gestation, were
obtained commercially from Advanced Biological Resources (ABR,
Alameda, CA). Detailed methods for the isolation of HpB have pre-
viously been described [26]. Briefly, liver tissue was enzymatically
digested at 378C using collagenase type IV (Worthington Biochem-
ical Corporation, Lake Wood, NJ) and deoxyribonuclease (Roche
Life Sciences, Mannheim, Germany). Following digestion, nonpar-
enchymal cells were separated from the parenchymal cell fraction
by density gradient centrifugation using Histopaque-1077 (Sigma-
Aldrich, St. Louis, MO). HpB (present in the lower fraction) were
re-suspended in Kubota’s hepatoblast growth medium (KM)
(PhoenixSongs Biologicals, Branford, CT), and plated on Collagen-
IV (5 lg/cm2) (Sigma-Aldrich, St. Louis, MO) and Laminin (1 lg/
cm2) (BD Biosciences, Sparks, MD) coated 15-cm culture plates
and incubated at 378C as previously described [10]. The upper
fraction containing fetal liver stromal cells (LvSt) was plated in
gelatin-coated tissue culture flasks in mesenchymal stem cell
growth media (MSCGM) (Lonza, Walkersville, MD). Culture plates
containing the different cell fractions were washed on the next
day to remove nonadherent cells, and were then maintained in
KM (HpB) or MSCGM (LvSt), respectively, for up to 7 days. The
cells were cultured and expanded, and flow cytometric analysis
demonstrated that LvSt displayed markers characteristic of a peri-
vascular mesenchymal cell/pericyte population that we and
others have identified in several different organs [27], including
CD146, CD105, CXCL12, CD90, and CD44.
Isolation and Culture of Adult BM-Derived Stromal
Progenitor Cells/Pericytes
Heparinized human BM was obtained from healthy donors after
informed consent according to guidelines from the Office of
Human Research Protection at Wake Forest University Health Sci-
ences. Low-density BMmononuclear cells (BMNC) were separated
by Ficoll density gradient (1.077 g/ml Sigma-Aldrich, St. Louis,
MO) centrifugation and washed twice in Iscove’s modified Dulbec-
co’s medium (Invitrogen, Carlsbad, CA). BMNC were first enriched
for the Stro-11 fraction using a Stro-1 antibody (R&D Systems,
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Minneapolis, MN) and magnetic bead cell sorting (Miltenyi Biotec,
Inc., Auburn, CA). Stro-11 cells were expanded in vitro at 378C in
5% CO2 humidified air, in MSCGM, using Fibronectin-coated tissue
culture flasks. At a confluence of 60%–75%, cells were detached
with 0.25% trypsin (Invitrogen Corp., Carlsbad, CA) for 3–5
minutes at 378C. Trypsin was neutralized with media containing
10% fetal bovine serum (Thermo Fisher Scientific, Grand Island,
NY), and cells were passaged at a 1:3 ratio into gelatin-coated tis-
sue culture flasks in MSCGM. Characterization by flow cytometry,
and by functional studies, demonstrated that these cells displayed
markers characteristic of BM-derived mesenchymal cells/peri-
cytes, including CD105, CD146, CXCL12, CD90, CD44, and CD29,
and that they were able to undergo trilineage differentiation into
adipocytes, cartilage, and bone [28].
Culture of HpB, LvSt, and Bone Marrow-Derived
Stromal Progenitor Cells on 3D-ECM Disks and on Tissue
Culture Plates (2D)
Bone marrow-derived stromal progenitor cells (BMSPC) and LvSt
were detached from culture plates using Trypsin-EDTA (Sigma-
Aldrich, Grand Island, NY), while HpB were harvested using colla-
genase IV (Worthington Biochemical Corporation, Lake Wood, NJ).
Sterilized 3D-ECM disks in 48-well plates were incubated with
either MSCGM or KM for 30–45 minutes prior to cell seeding, and
were then air-dried under sterile conditions. Cells were resus-
pended in the appropriate seeding medium and slowly pipetted
onto the top of each disk, and incubated for about an hour at
378C to allow cells to attach to the disks before adding appropri-
ate culture medium. Identical numbers of BMSPC or LvSt (26 0.5
3 105) were seeded in 3D-ECM disks and in 2D gelatin-coated 48-
well plates. HpB (26 0.9 3 105) were seeded onto collagen IV-
and laminin-coated 48-well tissue culture plates. Three days after
seeding, stromal cells in 3D and 2D cultures were inactivated by
treatment with 25 mg/ml Mitomycin-C (Sigma-Aldrich, St. Louis,
MO) for 30 minutes at 378C. After inactivation, cells in 2D and 3D
cultures were extensively washed with PBS to remove any residual
Mitomycin-C.
Isolation and Culture of CB CD341 Cells
Human CB samples were graciously provided by the NHLBI Bio-
logic Specimen and Data Repository Information Coordinating
Center. CB samples were thawed and CD341 cells isolated using
magnetic cell sorting using the CD34 ultra-pure microbead kit
(Miltenyi Biotec, Gladbach, Germany) following manufacturer’s
instructions. As determined by flow cytometric analysis, the per-
centage of CD341 cells after sorting varied little between the
experiments (67.7%6 5.4%). CD341-enriched cells were then
seeded in 48-well plates on top of 3D-ECM disks containing LvSt
and HpB in KM (PhoenixSongs Biologicals, Branford, CT) or KM
supplemented with 50nM of the GSK3i CHIR99021 (Tocris Bio-
sciences, Bristol, U.K.) and 10 mM Thiazovivin (Tocris Biosciences,
Bristol, U.K.) (KM1Drugs). CB-derived cells were also cultured in
48-well plates on top of confluent BMMSC, LvSt, or HpB, in 2D or
3D cultures, in QBSF-60 serum-free medium (Quality Biologicals,
Inc., Gaithersburg, MD) supplemented with stem cell factor (SCF)
(100 ng/ml), Fms-related tyrosine kinase 3 ligand (Flt-3L) (100 ng/
ml), leukemia inhibitory factor (LIF) (10 U/ml), and basic fibroblast
growth factor (bFGF) (5 ng/ml), at 378C and 5% CO2 humidified air
for 12 days (SFM).
Proliferative and Phenotypic Analysis of Ex Vivo
Expanded Cells
Nonadherent hematopoietic cells were harvested every other day.
Cell number was determined using a hemocytometer, and viability
was determined by Trypan Blue exclusion (Gibco, Grand Island,
NJ). Hematopoietic cells were stained according to manufacturer’s
instructions using the appropriate isotype controls and a panel of
fluorescein isothiocyanate (FITC)-conjugated anti-CD38, CD33, and
CD15; PE-conjugated anti-CD133, CD7, and CD14; and PerCP-
conjugated anti-CD34, CD3, and CD45 antibodies (all from BD Bio-
sciences, San Jose, CA) with the exception of the anti-CD133 anti-
body (Miltenyi Biotec, Gladbach, Germany). Stained cells were
then run on a FACScaliber (BD, San Jose, CA), and the resultant
data were analyzed using Cellquest software.
Methylcellulose Colony Assays
Methylcellulose colony assays were performed by plating 104 cul-
tured cells in 2 ml of MethoCult H4434 (Stem Cell technologies,
Vancouver, BC, Canada) culture medium. To determine the clono-
genic potential of each CB prior to culture, 104 freshly isolated
CD341 cells were also plated in MethoCult H4434 and grown
under identical conditions. The cultures were maintained at 378C
in a humidified atmosphere of 5% CO2 in air, and hematopoietic
colonies were identified and enumerated in situ at day 14 after
seeding, with a Zeiss Axiovert 40C inverted microscope.
Immunohistochemistry and Immunofluorescent
Staining of Liver Organoids
Liver organoids cocultured with CB-derived CD341 cells were har-
vested every week, fixed overnight with 10% Neutral-Buffered
Formalin (Sigma-Aldrich, Saint Louis, MO), and preserved in paraf-
fin blocks using standard techniques. H&E staining was performed
on 5-micron sections of the liver organoids after deparaffinization
and rehydration as previously reported [10].
Statistics and Data Analysis
Fold increase of total MNC was determined by dividing the num-
ber of total viable cells present at each specific day of analysis by
the initial viable cell count. Fold increase of various lineage cells
was calculated by multiplying the percentage of lineage-specific
cells by the count of total viable cells present at each specific day
of analysis, and dividing this number by the total number of
lineage-specific cells prior to culture.
Experimental results are presented as the mean plus/minus
the SEM, and were analyzed with Prism 6 (GraphPad Software,
Inc., La Jolla, CA). Statistical significance of differences observed
between the various experimental conditions were determined
using two-way analysis of variance (ANOVA) followed by the
Bonferonni-Sidak correction for multiple comparisons. A p value
<.05 was considered to be statistically significant.
RESULTS
Defining Culture Strategies to Support Both Functionally
Integrated 3D Microenvironments and Hematopoiesis
In order to maintain the viability of HpB seeded in 3D-ECM disks
(HpB-3D-ECM), and simultaneously coculture CB-HSPC, we first
determined the suitability of the culture media to be used. Three
different media formulations were tested in parallel, to determine
which was best able to both maintain HpB-3D-ECM and support
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the growth of CB-HSPC: (a) HpB-specific Kubota medium, alone
(KM) (n5 3); (b) KM in combination with CHIR99021, a potent
inhibitor of GSK3 and wingless-related integration site (WNT) acti-
vator, and Thiazovivin, a RHO/ROCK pathway inhibitor
(KM1Drugs) (n5 3), which was previously shown to support the
differentiation of ES cells into HpB [29]; and (c) serum-free media
(n5 3) [30] containing the cytokines Flt-3L, SCF, bFGF, and LIF
(SFM), which we had previously shown to promote the ex vivo
expansion of CB-HSPC grown over 2D stromal layers [4].
Weekly evaluation of the total number of viable mononuclear
cells present in the supernatant of the HpB 3D-ECM cultures using
each of the different media formulations demonstrated that SFM
was better able to support the growth of HSPC than KM or
KM1Drugs (Fig. 1A), and that SFM was able to preserve HpB-3D-
ECM constructs to the same extent as HpB-specific media (Fig.
1B). Since the dose of colony-forming units (CFU) is one of the
most important parameters influencing CB engraftment [31], we
evaluated the clonogenic potential of CB-HSPC in culture. Our
data show that the growth was optimal under SFM conditions.
Moreover, although the total number of mononuclear cells
increased with time throughout the duration of culture (Fig. 1A),
cells with both colony forming unit-granulocyte, erythrocyte, mac-
rophage, megakaryocyte (CFU-GEMM) and colony forming unit
granulocyte, macrophage (CFU-GM) potential were found to be
present during the first week (Fig. 1C, 1D, respectively).
During fetal development, the liver is a hematopoietic organ
[15, 16]; therefore, it was possible that the HpB used in these
experiments contained trace amounts of residual hematopoietic
cells, and could thus be providing additional numbers of HSPC to
the cultures. Microscopic and supernatant evaluation of cultures
of HpB-3D-ECM in the absence of CB-HSPC cultured in SFM, KM,
or KM1Drugs, at regular intervals after seeding, demonstrated
that cultures that had not been seeded with CB-HSPC were devoid
of any hematopoietic cells. These results thus confirmed that
there were no HSPC contaminants within the HpB preparations
that could be contributing to the observed HSPC expansion (Fig.
1E). In addition, since the ECM can also play a role in cell and tis-
sue behavior, by virtue of its ability both to arrange cells in a
highly-ordered 3D array, and to serve as a reservoir of growth fac-
tors and cytokines [32–34], CB-HSPC were also cocultured under
the same media conditions using “empty” acellular scaffolds
(n5 3).When grown under these conditions, the number and via-
bility of CB-HSPC rapidly decreased, and no viable hematopoietic
cells were obtained in these cultures, demonstrating that the cel-
lular components, and not residual cues present within the 3D-
ECM, were responsible for supporting CB-HSPC expansion
(Fig. 1E). In addition, and in similarity to our previous findings [35],
CB-HSPC grown in culture media alone did not proliferate and had
decreased viability with the time in culture (data not shown).
Influence of HpB-3D-ECM and HpB-2D Environments on
Expansion of the More Primitive CB-HSPC
Having determined that SFM was the best culture media to sup-
port HpB-3D-ECM, and established that the first week was the
optimal time frame to expand CD341 HSPC with enhanced clon-
ogenic potential, we next determined if HpB-3D-ECM and HpB-
2D cultures differed in their ability to support expansion of the
more primitive CB-HSPC. The total number and the fold increase
of CB-derived MNC during the first week in culture, with either
HpB-3D-ECM (n5 3) or HpB-2D (n5 3) is shown in Figure 2A. As
can be seen in this figure, total CB-derived MNC expansion was
similar between the two different culture systems, as assessed by
live cell fold increase at day 2 and 4. However, at day 6, HpB-2D
HSPC contained significantly higher numbers of MNC than their
HpB-3D-ECM HSPC counterparts (p< .05). The percentage of
CD341 cells in 2D and 3D cultures remained similar throughout
the time in culture (Fig. 2B), with the percentage of CD341 cells
decreasing by 29.7% and 20.5% in HpB-2D and HpB-3D-ECM,
respectively.
Despite these apparent similarities, however, differences
between 2D and 3D environments became readily apparent when
the more primitive fraction of HSPC were analyzed. During the
first week in culture, percentages of CD341 CD382 in HpB-3D-
ECM cultures, as determined by flow cytometric analysis, were
higher than in HpB-2D (day 2, p5 .8; day 6, p5 .9), and at day 4
of culture, this difference reached statistical significance (p< .05)
(Fig. 2C). In agreement with these results, the percentage of CFU-
GEMM colonies/1,000 cells was significantly higher at day 4 in cul-
ture (p< .05) (Fig. 2D) while no significant differences were seen
in the percentage of CFU-GM colonies/1,000 cells. In addition,
HpB-3D-ECM cultures favored expansion of CD331 cells over
other myeloid and lymphoid lineages (Supporting Information
Table S1). Also of note is that, in HpB-3D-ECM HSPC cultures, the
percentage of CFU-GEMM colonies/1,000 cells was significantly
higher at day 2 and 4 of culture than it was in the initial cell popu-
lation (Fig. 2D).
H&E staining performed on 3D-ECM disks at the end of the
culture period confirmed that 3D-ECM was cellularized through-
out the duration of the experiment (Fig. 2E).
Comparison of the Ability of LvSt-3D-ECM and LvSt-2D
Environments to Support CB-HSPC Populations
It has been reported that fetal liver pericytes and stromal cell
lines play an important role in promoting CB expansion and fetal
hematopoiesis [3]. Therefore, we next investigated whether 3D
environments prepared with human fetal liver stromal cells (LvSt-
3D-ECM) could also support the expansion of CD341 CD382 CB-
derived cells. No significant difference was found between the
LvSt-3D-ECM (n5 3) and LvSt-2D culture system (n5 3) regarding
total CB-derived MNC expansion (Fig. 3A), or the percentage of
CD341 cells (Fig. 3B). In similarity to the HpB-based 3D microen-
vironment, LvSt-3D-ECM supported the more primitive fraction of
HSPC. At day 2 and 4 of culture, the percentage of CD341 CD382
cells in LvSt-3D-ECM HSPC cultures was significantly higher
(p< .05) than in their LvSt-2D counterparts (Fig. 3C). While the
percentage of CFU-GEMM colonies/1,000 cells was significantly
higher at day 4 in LvSt-3D-ECM HSPC cultures (Fig. 3D), on that
same day the percentage of CFU-GM colonies/1,000 cells was sig-
nificantly higher in the LvSt-2D HSCP cultures (p< .05). Both LvSt-
3D-ECM and LvSt-2D supported the differentiation of cells with
myeloid and lymphoid phenotypes (Supporting Information Table
S1). As with the HpB-3D-ECM cultures, H&E staining was per-
formed on LvSt-3D-ECM disks at the end of the cultures to verify
that 3D-ECM was present and cellularized throughout the dura-
tion of the experiment (Fig. 3E)
Ability of BMSPC-3D-ECM and BMSPC-2D Environments
to Support CB-HSPC Populations
Since we had previously used BMSPC to successfully create 2D
environments that expanded CB cells, we next investigated
whether BMSPC were able to colonize 3D liver-derived extracellu-
lar matrix scaffolds, and to evaluate how HSPC cultured on these
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Figure 1. Defining culture strategies to support both functionally integrated 3D microenvironments and hematopoiesis. (A): Results from a
representative experiment demonstrating the weekly evaluation of the total number of viable mononuclear cells in the supernatants of HpB
3D-ECM cultures using the various media formulations in a representative experiment. (B): Microscopic evaluation of viability of HpB-3D-
ECM constructs with different media, demonstrating that KM, KM1Drugs, and SFM were all able to preserve HpB-3D-ECM constructs.
(C, D): Results from the same representative experiment demonstrating clonogenic potential of CB-HSPC in culture; CFU-GEMM (C) and CFU-
GM potential (D) was optimal under SFM conditions, and occurred during the first week. (E): Microscopic evaluation of cultures of HpB-3D-
ECM, in the absence of CB-HSPC, using SFM, KM, or KM1Drugs, demonstrated that cultures that had not been seeded with CB-HSPC did
not contain any hematopoietic cells. Transmitted light images were captured at 310 with an Olympus IX-70 microscope. Abbreviations: 3D-
ECM, three-dimensional liver-extracellular-matrix; CB-HSPC, cord blood-derived hematopoietic stem/progenitor cells; CFU-GEMM, colony
forming unit-granulocyte, erythrocyte, macrophage, megakaryocyte; CFU-GM, colony forming unit granulocyte, macrophage; HpB, hepato-
blasts; KM, Kubota’s hepatoblast growth medium; SFMC, serum-free media1cytokines (Flt-3L, SCF, bFGF, and LIF).
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BMSPC-3D-ECM would compare to their 2D counterparts. The
total number and the fold increase in CB-derived MNC during the
first week in culture with BMSPC-3D-ECM (n5 3) and BMSPC-2D
(n5 3) is shown in Figure 4A. As can be seen, the total CB-derived
MNC expansion, as assessed by live cell fold increase, was similar
between the two different cultures until day 4, but at day 6,
BMSPC-2D contained significantly higher total cell numbers than
BMSPC-3D-ECM HSPC cultures (p< .05). The percentage of
CD341 cells in 2D and 3D cultures remained similar throughout
the time in culture, and was maintained from day 0 to day 6 (Fig.
4B). In similarity to what we had observed with the other 3D cul-
ture systems, BMSPC-3D-ECM maintained significantly higher
Figure 2. Influence of HpB-3D-ECM and HpB-2D environments on expansion of the more primitive CB-HSPC. (A): Cell and fold increase in
total number of CB-derived MNC during the first week in culture; at day 6, HpB-2D HSPC contained significantly higher numbers of HSPC
than their HpB-3D-ECM counterpart (*, p< .05). (B): Percentage of CD341 cells in 2D and 3D cultures. (C): Daily percentages of
CD341 CD382 cells in HpB-3D-ECM cultures are higher than in HpB-2D (day 2, p5 .8; day 6, p5 .9; day 4 (*, p< .05). (D): Percentage of
CFU-GEMM colonies/1,000 cells during the first week in culture; the percentage of CFU-GEMM colonies/1,000 cells was significantly higher
at days 2 and 4 of culture than in the initial cell population (**, p< .05); comparison between 2D and 3D environments 3D environments
showed had significantly higher percentage of CFU-GEMM colonies/1,000 cells at day 4 in culture than their 2D counterpart (*, p< .05). (E):
Percentage of CFU-GM colonies/1,000 cells. (F): H&E staining performed on HpB-3D-ECM disks on the last day of cultures confirmed that
HpB-3D-ECM was cellularized throughout the duration of the experiment. Abbreviations: 3D-ECM, three-dimensional liver-extracellular-
matrix; CB-HSPC, cord blood-derived hematopoietic stem/progenitor cells; CFU-GEMM, colony forming unit-granulocyte, erythrocyte, macro-
phage, megakaryocyte; CFU-GM, colony forming unit-granulocyte, macrophage; HpB, hepatoblasts; MNC, mononuclear cells.
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percentages of CD341 CD382 cells than 2D cultures (day 2,
p< .05; day 4, p< .05) (Fig. 4C). However, in these BMSPC-based
cultures, the percentages of CFU-GEMM and CFU-GM colonies/
1,000 cells were similar in 2D and 3D conditions Figure 4D and 4E,
respectively. In addition, as we had observed with the HpB-3D-
ECM, the BMSPC-3D-ECM also favored increase of CD331 cells
over other myeloid and lymphoid lineages (Supporting Informa-
tion Table S1). As in the prior experiments, H&E staining con-
firmed that the BMSPC-3D-ECM disks were cellularized
throughout the duration of culture (Fig. 4E).
Figure 3. Comparison of the ability of LvSt-3D-ECM and LvSt-2D environments to support cord blood-derived hematopoietic stem/progeni-
tor cells (CB-HSPC) populations. (A): Cell and fold increase in total number of CB-derived MNC during the first week in culture. No significant
difference was observed between the LvSt-3D-ECM and LvSt-2D culture system, regarding total CB-derived MNC expansion. (B): Percentage
of CD341 cells in 2D and 3D cultures. (C): Daily percentages of CD341 CD382 cells were significantly higher (*, p< .05) at days 2 and 4 of
culture in LvSt-3D-ECM than in LvSt-2D. (D): Percentage of CFU-GEMM colonies/1,000 cells was significantly higher at day 4 in LvSt-3D-ECM
HSPC cultures (*, p< .05) when compared to their 2D counterpart. (E): The percentage of CFU-GM colonies/1,000 cells was significantly
higher (*, p< .05) at day 4 of culture in LvSt-2D compared to the LvSt-3D-ECM. (F): H&E staining on LvSt-3D-ECM disks at the conclusion of
the cultures demonstrated that LvSt-3D-ECM was cellularized throughout the duration of the experiment. Abbreviations: 3D-ECM, three-
dimensional liver-extracellular-matrix; CFU-GEMM, colony forming unit-granulocyte, erythrocyte, macrophage, megakaryocyte; CFU-GM, col-
ony forming unit-granulocyte, macrophage; LvSt, fetal liver stromal cells; MNC, mononuclear cells.
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Comparison of the Influence of HpB-3D-ECM,
LvSt-3D-ECM, and BMSPC-3D-ECM on CB-HSPC
Having determined that a 3D-ECM environment, regardless of the
cell type, favored the maintenance of HSC with a more primitive
phenotype, we next compared the impact of the different cell
types used to create the 3D-ECM environments, on expansion and
differentiation of CB-HSPC.
The fold increase in total number of CB-derived MNC dur-
ing the first 2 weeks in culture with HpB-3D-ECM (n5 3),
LvSt-3D-ECM (n5 3), and BMSPC-3D-ECM (n5 3) is shown in
Figure 4. Ability of BMSPC-3D-ECM and BMSPC-2D environments to support cord blood-derived hematopoietic stem/progenitor cells (CB-
HSPC) populations. (A): Cell and fold increase in total number of CB-derived MNC during the first week in culture; at day 6, BMSPC-2D con-
tained significantly higher numbers of HSPC than their BMSPC-3D-ECM counterpart (*, p< .05). (B): Percentage of CD341 cells in 2D and 3D
cultures. (C): BMSPC-3D-ECM contained significantly higher percentages of CD341 CD382 cells than 2D cultures (day 2, *, p< .05; day 4, *,
p< .05). (D): Percentage of CFU-GEMM colonies/1,000 cells. (E): Percentage of CFU-GM colonies/1,000 cells. (F): H&E staining on BMSPC-3D-
ECM disks at the conclusion of the cultures demonstrated that BMSPC-3D-ECM was cellularized throughout the duration of the experiment.
Abbreviations: 3D-ECM, three-dimensional liver-extracellular-matrix; BMSPC, bone marrow-derived stromal progenitor cells; CFU-GEMM, col-
ony forming unit-granulocyte, erythrocyte, macrophage, megakaryocyte; CFU-GM, colony forming unit-granulocyte, macrophage; MNC,
mononuclear cells.
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Figure 5A. During the first 6 days of culture, the total CB-
derived MNC expansion, as assessed by live cell fold increase,
was similar between the different cultures systems. However,
extension of this evaluation to the second week of culture
demonstrated that, at day 12, LvSt-3D-ECM contained signifi-
cantly higher numbers of MNC than BMSPC-3D-ECM or HpB-
3D-ECM (p< .05). The percentage of CD341 cells was signifi-
cantly higher in BMSPC-3D-ECM (p< .05) at day 4 of culture
Figure 5. Comparison of the influence of HpB-3D-ECM, LvSt-3D-ECM, and BMSPC-3D-ECM on cord blood-derived hematopoietic stem/pro-
genitor cells (CB-HSPC). (A): Fold increase in total number of CB-derived mononuclear cells (MNC) was similar between the different cultures
systems during the first 6 days of culture, but extension of this evaluation to the second week of culture demonstrated that, at day 12, LvSt-
3D-ECM contained significantly higher numbers of MNC than BMSPC-3D-ECM or HpB-3D-ECM (*, p< .05). (B): The percentage of CD341
cells was significantly higher in BMSPC-3D-ECM (*, p< .05) at day 4 of culture when compared to LvSt-3D-ECM or HpB-3D-ECM, and at day
12, all cultures still contained CD341 cells. (C): The percentage of CD341 CD382 cells at day 2 was higher in LvSt-3D-ECM cultures when
compared to HpB-3D-ECM (*, p< .05); At day 4, BMSPC-3D-ECM cultures contained significantly higher numbers of CD341 CD382 cells
than those with either BMSPC-3D-ECM or HpB-3D-ECM (*, p< .05); At day 12, only LvSt-3D-ECM cultures and HpB-3D-ECM contained
CD341 CD382 cells. (D): The percentage of CFU-GEMM/1,000 cells was similar for all 3D-ECM cultures, but only in LvSt-3D-ECM were the
percentages of CFU-GM/1,000 cells on days 2 and 4 significantly higher than they had been on day 0 (*, p< .05). (E): The percentage of CFU-
GM/1,000 cells, at day 12, was higher in LvSt-3D-ECM and BMSPC-3D-ECM when compared to HpB-3D-ECM on the same day. (F): Visualiza-
tion of the different 3D-ECMs demonstrated that, at day 12, all of the constructs were still populated with cells. Abbreviations: 3D-ECM,
three-dimensional liver-extracellular-matrix; BMSPC, bone marrow-derived stromal progenitor cells; CFU-GEMM, colony forming unit-granulo-
cyte, erythrocyte, macrophage, megakaryocyte; CFU-GM, colony forming unit-granulocyte, macrophage; HpB, hepatoblasts; LvSt, fetal liver
stromal cells.
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when compared to LvSt-3D-ECM and HpB-3D-ECM, and at day
12, all cultures still contained CD341 cells (Fig. 5B). LvSt-3D-
ECM cultures contained higher percentages of CD341 CD382
cells at day 2, when compared to HpB-3D-ECM (p< .05), and
by day 4, BMSPC-3D-ECM cultures contained significantly
higher numbers of CD341 CD382 than those with LvSt-3D-
ECM and HpB-3D-ECM (Fig. 5C). Of note is that, by day 12,
only LvSt-3D-ECM cultures and HpB-3D-ECM contained
CD341 CD382 cells. The percentage of CFU-GEMM/1,000 cells
was similar for all 3D-ECM cultures (Fig. 5D), but the percent-
age of CFU-GM/1,000 cells, at day 12, was higher in LvSt-3D-
ECM and BMSPC-3D-ECM when compared to HpB-3D-ECM
(Fig. 5E). However, only in LvSt-3D-ECM was the percentage of
CFU-GM/1,000 cells significantly higher than at day 0 (Fig. 5E).
The only significant differences seen when evaluating numbers
of mature myeloid cells during the time in culture occurred
on day 10, when LvSt-3D-ECM contained significantly more
CD151 cells than BMSPC-3D-ECM (p< .05) or HpB-3D-ECM
(p< .05), and on day 12, when LvSt-3D-ECM contained signifi-
cantly more CD331 and CD141 cells, than BMSPC-3D-ECM
(p< .05) or HpB-3D-ECM (p< .05) (Supporting Information
Table S2). To rule out the possibility that the differences
observed at day 12 were simply due to loss of the microenvir-
onmental niches, the respective 3D-ECMs were visualized
microscopically, which confirmed that the constructs were still
populated with cells at day 12 of culture (Fig. 5E).
DISCUSSION
For the past 20 years, CB-HSPC have served as a reliable source
of hematopoietic stem and progenitor cells to treat malignant
and nonmalignant disorders [36]. The advantages of using CB
as a source of transplantable HSPC include the increased likeli-
hood of a patient finding a compatible donor, its lower risk of
inducing graft-versus-host disease, its ready availability, and
the reduced probability of transmitting viral infections [36].
Still, the relatively low number of HSPC per CB unit, and the
delayed kinetics of engraftment have hindered the use of CB-
HSPC in adolescents and adults. Since the first CB transplant
was performed more than 20 years ago [37], new strategies
have been developed in an effort to overcome this limitation.
The first attempts at ex vivo expansion of CB-HSPC used growth
factors alone, and led to inadequate outcomes. However,
when patients were transplanted with HSPC that had been
cocultured in the presence of supportive stromal layers, the
time to neutrophil and platelet reconstitution was significantly
shortened [38]. Other approaches to expand the numbers of
transplantable HSPC within a unit of CB have included or
involved activation of endogenous Notch receptors [39], nico-
tinamide analogs [40], aryl hydrocarbon receptor antagonists
[41], copper chelators [1], histone deacetylase inhibitors [42],
and engraftment enhancers such as PEG2 [43] and CXCR4 [44].
These newer approaches have all shown great potential for the
ex vivo expansion of CB-HSPC or accelerating their engraft-
ment. Still, expansion of the true hematopoietic stem cell pool
has been limited [2, 4, 45, 46]. We [4–7] and others [38] have
previously shown that CB-HSPC can be effectively expanded
and driven to differentiate toward both the myeloid and
lymphoid lineages in a serum-free culture system, using a
feeder layer of adult human BM-derived stromal cells. Using
this system, we have optimized initial progenitor content and
cytokine concentrations [7–9], and demonstrated that the
expanded human CB-HSPC had the ability to engraft pre-
immune fetal sheep [5]. While the relative number of long-
term engrafting HSC increased in this culture system, still, the
absolute percentage growth of these most primitive stem cells
decreased with time.
The importance of the composition and architecture of the
microenvironment in inducing cell division/differentiation or
expansion of CB-HSPC has been demonstrated by the use of
mixed feeder layers within the same 2D culture [47], acellular
matrices [48], and 3D culture systems [49–52]. Nevertheless, the
challenge of expanding long-term repopulating HSC from a single
unit, in such a way that sufficient numbers of HSC will be obtained
to engraft an adult, while simultaneously increasing progenitor
populations that are able to shorten time to engraftment, has yet
to be solved [1, 2].
In the present study, we used natural 3D liver ECM scaffolds
to recreate microenvironments that are known, during fetal
development, to promote the expansion of true long-term
repopulating HSC. In these unique constructs, human fetal liver
progenitor cells self-assemble inside the ECM-derived scaffolds
to form 3D liver organoids that recapitulate several aspects of
the hepato-biliary ontogeny [14]. Moreover, since controlled
cellular alignment plays a role in the biology and function of a
tissue, the 3D liver scaffolds repopulated with single liver-
derived cells, or other cell types, also provide a model system in
which to test the role of 3D architecture and ECM components
in the balance between the preservation and the differentiation
of primitive CB-HSPC. The results show that ECM alone was
either unable to support the viability, or inhibited the growth,
of HSPC in culture, demonstrating that the presence of cellular
components within the scaffolds was necessary for HSPC sup-
port. Analysis of the effects of different cellular microenviron-
ments on HSPC, showed that, during the first 5 days of culture,
total HSPC numbers did not vary considerably between 2D and
3D cultures. However, at day 6, BMSPC-2D and HpB-2D cultures
contained significantly higher numbers of HSPC than BMSPC-
3D-ECM and HpB-3D-ECM, respectively. At this time point, LvSt-
3D-ECM had significantly higher numbers of HSPC than other
3D cultures, but not when compared with LvSt-2D-ECM, sug-
gesting that LvSt-derived cells themselves are better able to
support HSPC.
Analysis of the absolute percentage growth of CD341 cells
during the time in culture demonstrated that the 3D architecture
did not significantly impact this outcome, which is in agreement
with what has been reported with other types of 3D culture sys-
tems [51, 52].
While in vivo studies will be necessary to confirm that 3D
microenvironments do not alter the ability of cultured HSPC
populations to engraft, we were able to show that all of the
3D-ECM platforms contained significantly higher percentages of
CD341 CD382 cells than their 2D counterparts, demonstrating
that, irrespectively of the microenvironment used, the 3D-ECM
structure led to the maintenance of a more primitive subpopu-
lation of HSPC. In addition, longer-term maintenance of
CD341 CD382 cells (12 days), and the significantly higher per-
centage of CFU-GEMM colony output in HpB-3D-ECM and LvSt-
3D-ECM also demonstrated that the combination of 3D-ECM
organization with liver-derived cells preserved the more primi-
tive HSPC during the time in culture. Of note is that only in
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HpB-3D-ECM cultures was the percentage of CFU-GEMM/1,000
cells significantly higher at day 2 and 4 than in the initial HSPC
population, suggesting that HSPC-HpB-3D-ECM cultures not only
maintained, but supported the increase in functional immature
multipotent hematopoietic progenitor cells. Furthermore, short-
term evaluation of HSPC differentiation showed that, overall,
3D microenvironments were more efficient at sustaining earlier
myeloid progenitors; while extending the time in culture to 2
weeks revealed that LvSt-3D-ECM was the most efficient envi-
ronment for promoting the production of CD33, CD14, and
CD15 positive cells.
CONCLUSION
This study shows that the integration of cellular components
with cellular components derived from microenvironmental
niches was necessary for maintenance of HSPC viability in cul-
ture. Irrespective of the microenvironments used, the 3D-ECM
structures led to the maintenance of a more primitive subpopu-
lation of HSPC, as determined by flow cytometry and colony
forming assays. In addition, the timing and extent of expansion
depends upon the cellular component used, with HpB, promot-
ing the increase of, functional immature multipotent hemato-
poietic progenitor cells, and LvSt providing the optimal balance
between preservation of primitive CB HSPC and cell
differentiation.
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